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Introduction 
Jet nebulizers are used to deliver a variety of 
drugs to the lower respiratory tract. The majority of 
droplets generated during the initial atomization 
process are too large to penetrate into the lower 
airways and hence baffles within nebulizers are used 
to generate droplets that fall within the ‘respirable 
range’ of l-5 pm (1). In certain situations such as 
the ‘alveolar targeting’ of drugs such as pentami- 
dine (2), it is desirable to generate droplets <3,~rn 
in size. The use of such aerosols may also be useful 
in the treatment of patients with a variety of 
chronic obstructive airways diseases. It is known 
that for patients with cystic fibrosis and other such 
conditions, deposition of aerosols becomes increas- 
ingly more central as the disease progresses (1,3). 
There is evidence to suggest that finer droplets 
(<3,~m) may penetrate more effectively to the lung 
peripheries in these patients. 
The standard method of generating fine aerosols, 
using jet nebulizers, has been to increase the effective- 
ness of the baffles within the system. However, the 
use of more effective baffles within the nebulizer itself 
substantially increases the time taken for a dose to be 
nebulized, while the use of an external baffle placed 
between the nebulizer and patient reduces the total 
dose of drug delivered. A new approach was sought 
in order to generate fine aerosols while maintaining 
the relatively high rates of drug delivery characteristic 
of conventional jet nebulizers. 
An auxiliary chamber (volume 1 1) was designed 
(Fig. 1) to be used with any conventional jet 
nebulizer. Adjacent to the nebulizer inlet is a one-way 
entrainment valve and an inlet for an auxiliary 
‘drying’ air supply. As with the nebulizers driving 
gas flow (DGF), the ‘drying’ flow could be varied 
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Fig. 1 Auxiliary ‘drying’ chamber for use with conven- 
tional jet nebulizer. 
as required. A series of experiments were performed 
in order to assess the effect on particle size of 
independently altering the DGF and ‘drying’ flow. 
Method and Results 
A Malvern 2600 particle sizer utilizing the 
Fraunhofer diffraction model was used to measure 
particle size. Two drugs in solution, gentamicin 
(80 mg 2 ml - ‘) and pentamidine, and one drug sus- 
pension, budesonide (250 mg ml - ‘) were used. The 
DGF and drying flow were supplied by compressed 
air cylinders with appropriately calibrated flow 
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Table I Mass median diameters of aerosols generated by a Cirrus nebulizer with auxiliary 
‘drying’ chamber when independently varying the driving gas and ‘drying’ gas flows. Percent- 
ages of droplet mass contained within droplets < 1.22 and c4.97 pm are given for gentamicin 
Driving Drvine 
Gentamicin Pentamidine Budesonide 
gas - 
flow 
gas - 
flow MMD 
% droplet 
mass i 1.22 
% droplet 
mass c4.97 MMD MMD 
6 0 5.4 11.4 36.6 5.3 5.4 
6 6 2.2 24.8 97.5 
6 8 1.8 32.5 98.4 1.9 1.8 
8 0 4.4 17.4 56.3 4.4 4.5 
8 6 3.9 15.7 61.6 
8 8 1.4 42.3 95.3 1.2 1.8 
8 10 1.3 45.1 96.8 1.1 1.5 
10 0 2.6 21.9 75.9 2.5 2.5 
10 8 2.1 31.9 84.6 
10 12 1.2 49.5 95.3 1.1 1.86 
MMD, mass median diameter. 
meters (BOC Medishield). A single Cirrus nebulizer 
(Intersurgical) was used for all the experiments. 
Three experiments were performed under each set of 
conditions. 
Results obtained when nebulizing these drugs 
using varying DGF’s and ‘drying’ flows are presented 
in Table 1. The mass median diameter (MMD) is the 
value such that one-half of the droplet mass is 
contained in larger droplets and one-half in smaller 
droplets. With no drying flow, the MMD increases as 
the DGF increases. 
For each DGF, the MMD of the aerosol leaving 
the device is substantially reduced when the drying 
flow is sufficient to cause evaporation of water from 
the droplets. For all DGFs, MMDs of less than 
1.5,~rn can be achieved, the drying flow required 
being dependent upon the DGF. 
Discussion 
These results suggest that a simple drying chamber 
can be used with a variety of drug solutions and 
suspensions to significantly reduce the size of drug 
containing droplets being delivered to patients. Such 
a system is likely to significantly enhance deposition 
of drug in the lung peripheries, particularly in 
patients with airways obstruction, and reduce depo- 
sition in the upper and central conducting airways. 
Hence it may be of value in a variety of situations 
including drug delivery in patients with cystic fibrosis 
and the administration of drugs, such as pentami- 
dine, which have unpleasant side-effects if deposited 
centrally. 
The principle of ‘drying’ an aerosol is not novel but 
this is the first description we are aware of in which 
the principle has been applied to small volume jet 
nebulizers. The small particle aerosol generator 
(SPAG) is used for delivering ribavirin to infants 
with bronchiolitis (4) and it is believed that drying of 
the aerosol promotes delivery of the drug to the 
peripheral airways of small infants. However, this 
system is cumbersome and is designed for nebulizing 
large volumes of solutions over prolonged periods. 
The auxiliary chamber described here can be used 
with any conventional jet nebulizer using standard 
volumes of solution, and achieves greater rates of 
drug delivery than are possible with the SPAG. 
The ‘dried’ particles generated by this system will 
be subjected to hygroscopic growth when they enter 
the respiratory tract but it has been estimated that 
hygroscopic growth is not significant until beyond 
the sixth generation of airways when mouth breath- 
ing (5). Hence mouth breathing will enhance periph- 
eral penetration when inhaling hygroscopic aerosols. 
Theoretical calculations and experimental work 
suggests that for significantly hygroscopic droplets, 
the minimum likelihood of deposition in the airway is 
approximately 0.1 pm rather than 0.5 pm and that 
maximal alveolar deposition occurs in the range 
0.5-1.5pm (6). This range is very similar to droplet 
sizes that can be generated with this system. 
A chamber such as this would act as a ‘holding’ 
chamber and hence would not only generate aerosols 
with a low MMD but would enhance drug delivery in 
adults by increasing the volume of aerosol that is 
available to be inhaled (7,8). 
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be of value in situations in which it is desirable to 
deliver drugs as an aerosol with a low MMD, whilst 
still maintaining a high rate of drug delivery. 
